- Home
- WIW vs FTRE Comparison
WIW vs FTRE Comparison
Compare WIW & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIW
- FTRE
- Stock Information
- Founded
- WIW 2004
- FTRE 1996
- Country
- WIW United States
- FTRE United States
- Employees
- WIW N/A
- FTRE N/A
- Industry
- WIW Finance Companies
- FTRE Medical Specialities
- Sector
- WIW Finance
- FTRE Health Care
- Exchange
- WIW Nasdaq
- FTRE Nasdaq
- Market Cap
- WIW 537.8M
- FTRE 469.0M
- IPO Year
- WIW N/A
- FTRE N/A
- Fundamental
- Price
- WIW $8.61
- FTRE $6.15
- Analyst Decision
- WIW
- FTRE Hold
- Analyst Count
- WIW 0
- FTRE 11
- Target Price
- WIW N/A
- FTRE $18.00
- AVG Volume (30 Days)
- WIW 229.9K
- FTRE 2.4M
- Earning Date
- WIW 01-01-0001
- FTRE 05-12-2025
- Dividend Yield
- WIW 11.14%
- FTRE N/A
- EPS Growth
- WIW N/A
- FTRE N/A
- EPS
- WIW N/A
- FTRE N/A
- Revenue
- WIW N/A
- FTRE $2,696,400,000.00
- Revenue This Year
- WIW N/A
- FTRE N/A
- Revenue Next Year
- WIW N/A
- FTRE $3.32
- P/E Ratio
- WIW N/A
- FTRE N/A
- Revenue Growth
- WIW N/A
- FTRE N/A
- 52 Week Low
- WIW $8.01
- FTRE $4.77
- 52 Week High
- WIW $9.37
- FTRE $37.24
- Technical
- Relative Strength Index (RSI)
- WIW 51.01
- FTRE 46.07
- Support Level
- WIW $8.58
- FTRE $5.40
- Resistance Level
- WIW $8.66
- FTRE $6.38
- Average True Range (ATR)
- WIW 0.07
- FTRE 0.45
- MACD
- WIW 0.01
- FTRE 0.21
- Stochastic Oscillator
- WIW 57.89
- FTRE 83.09
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.